United States: Federal Circuit Reverses "Inherency" Obviousness Ruling In Hatch-Waxman Lawsuit

In a July 17, 2017, precedential opinion, Millennium Pharmaceuticals, Inc. v. Sandoz Inc., the U.S. Court of Appeals for the Federal Circuit reversed and remanded an invalidity decision by the Delaware District Court.1 Millennium is the exclusive licensee of the '446 patent, which claims a lyophilized compound that is a boronate ester of bortezomib, a drug product that may be administered for the treatment of certain cancers. Numerous defendants, including Sandoz, filed ANDAs seeking FDA approval for generic versions of the drug, alleging that the patent's claims were invalid based on obviousness. While bortezomib and its efficacy against various cancers were known, drug products using bortezomib had never achieved FDA marketing approval because of problems with the compound's instability, rapid degradation, and insolubility. The district court decided that the patent's claims were obvious "because they were the inherent result of an allegedly obvious process, viz., lyophilizing bortezomib in the presence of the bulking agent mannitol." But in reversing the district court, the Federal Circuit reasoned that, among other things, the prior art did not teach or suggest "making the claimed new compound," that the "compound would be formed," or that the "compound would have the properties of stability, solubility, and dissociability that it exhibited." Further, the Federal Circuit found that secondary considerations, such as unexpected results and the existence of a long-felt but unmet need, constituted objective evidence of nonobviousness.

The '446 patent describes a compound that is a boronate ester of bortezomib (a boronic acid) and D-mannitol (a hydroxyl compound). The patent claims the lyophilized (freeze-dried) compound, the compound as a lyophilized cake, the method of preparing the compound, and its reconstitution with a pharmaceutically acceptable carrier. Bortezomib was known in the prior art as a proteasome inhibitor that was effective at treating various cancers; however, compounds of bortezomib never achieved FDA approval due to their instability and insolubility. Mannitol was also known in the prior art, but as a bulking agent used with other active ingredients. The inventors of the '446 patent purportedly discovered that by lyophilizing bortezomib with mannitol, the resulting ester acts as a prodrug, i.e., a stable compound that converts to or releases the active ingredient upon administration to a patient. The bortezomib ester compound was developed into the FDA-approved drug product Velcade®.

The district court invalidated the asserted claims of '446 patent based on obviousness. First, the district court found that the process of lyophilization was well-known in the field of pharmaceutical formulation, and that lyophilization was "considered as an obvious alternative" when liquid formulations were unsuccessful. Second, the district court decided "that the claims were obvious because they were an inherent result" of the lyophilization process. Finally, the district court decided that Millennium failed to establish secondary considerations of nonobviousness because: (1) "Millennium did not establish unexpected results because it did not compare the claimed invention to a glycerol ester of bortezomib" and (2) "'the lyophilized mannitol ester of bortezomib did not solve any problem having persisted over a long period of time without resolution by the prior art.'"2

The Federal Circuit rejected each of the district court's findings. First, the Federal Circuit determined that the prior art contained no teaching or suggestion of the compound described by the '446 patent, or that the compound would solve any of the insolubility and instability issues that the prior art associated with bortezomib. Furthermore, the Federal Circuit found that "[n]o reference shows or suggests ester formation at freeze-drying conditions." Under the circumstances here, the Federal Circuit agreed with Sandoz's characterization that "lyophilization was generally known in formulating pharmaceutical products" and that "bulking agents were known for use in lyophilization, and that mannitol was a known bulking agent." However, the Federal Circuit explained that for the compound to be obvious, the prior art must "teach or suggest that lyophilization of bortezomib in the presence of mannitol" would "form a new chemical compound," "provide a reason to make this new chemical compound," or demonstrate that this compound would "solve the previously intractable problems of bortezomib formulation."3 The Federal Circuit found that Sandoz did not persuasively meet its burden to show these facts. Indeed, the Federal Circuit stated that "[a]lthough mannitol was a known bulking agent, and lyophilization was a known method of drug formulation, nothing on the record teaches or suggests that a person of ordinary skill should have used mannitol as part of a synthetic reaction to make an ester through lyophilization."4 Accordingly, the Federal Circuit decided that "[t]he district court clearly erred in its obviousness analysis."

The Federal Circuit also found that "[n]o reference supports the district court's conclusion that 'skilled formulators would be motivated to create a mannitol ester to improve bortezomib's stability and solubility'" because there was nothing in the prior art that "suggest[ed] producing this ester for this purpose."5 The Federal Circuit took specific note of an expert's testimony that "Millennium could not have predicted that bortezomib would be stabilized by forming the mannitol ester." Sandoz had argued that since "mannitol is one of a relatively small number of bulking agents used in lyophilization," a person of ordinary skill was sufficiently motivated to arrive at the claimed invention. But the Federal Circuit found that "Sandoz provides no reason why a person of ordinary skill who is seeking to make esters of bortezomib would look to lyophilization bulking agents" because "there was no expectation that "the bulking agent [would] react with the bortezomib to form a new compound." Thus, the Federal Circuit concluded that "neither the requisite motivation nor expectation of success is found in the prior art."6

Further, the Federal Circuit stated that "[t]he district court clearly erred in its determination that lyophilizing bortezomib with mannitol to form an ester was a 'suitable option from which the prior art did not teach away.'"7 In particular, the Federal Circuit decided that "Millennium offered persuasive evidence that the chemical modification of bortezomib would have been unattractive to a person of ordinary skill for fear of disturbing the chemical properties whereby bortezomib functions effectively as an anti-cancer agent; in particular, a person of ordinary skill would have noted that the ester blocks a portion of the bortezomib molecule." Accordingly, "[w]ithout the knowledge that the D-mannitol bortezomib ester dissociates in the bloodstream at a rate of pharmaceutical efficacy, a person of ordinary skill would not have been led to create the ester." Thus, "a person of ordinary skill would have avoided creating an ester with mannitol because several different esters, each with different chemical and possibly biological properties, could have formed."

The Federal Circuit also explained that the district court erred in its consideration of inherency. Sandoz argued "that although lyophilization in the presence of mannitol produced an unexpected result, the result was 'inevitable' and thus 'inherent,' and thus not 'inventive.'" Rejecting this contention, the Federal Circuit stated that "invention is not a matter of what the inventor intended when the experiment was performed; obviousness is measured objectively in light of the prior art, as viewed by a person of ordinary skill in the field of the invention."8 Therefore, the invention was nonobvious because "[n]o expert testified that they foresaw, or expected, or would have intended, the reaction between bortezomib and mannitol, or that the resulting ester would have the long-sought properties and advantages."9

Finally, the Federal Circuit found that the district court erred in its examination of secondary considerations of nonobviousness, which included arguments concerning unexpected results, long-felt but unsolved need, and commercial success.

Regarding unexpected results, the district court compared the dissolution, stability, and solubility of the claimed mannitol ester of bortezomib to what it determined to be the closest prior art—a glycerol bortezomib ester. The district court erroneously determined that "bortezomib itself was not the closest prior art, and declined to consider the advantages and benefits of the Velcade® product." The Federal Circuit found that this "error" stemmed from the district court's determination that "Millennium should have compared the glycerol bortezomib ester" because a prior art reference "included glycerol as one of ten preferred dihydroxy compounds for boronate esters."10 However, the Federal Circuit found the district court's comparison misplaced because the "glycerol bortezomib ester was not specifically disclosed, prepared, or tested" in the prior art reference. Additionally the prior art reference did not "disclose the stability or solubility of any ester compound." The Federal Circuit explained that "[u]nexpected results are shown in comparison to what was known, not what was unknown." Properly comparing the claimed mannitol ester of bortezomib to the next closest prior art, i.e., bortezomib itself, the Federal Circuit found that the claimed compound "exhibited unexpected results," including "unexpectedly superior stability, solubility, and dissolution."11

The Federal Circuit also stated that "[t]he district court's conclusion that the lyophilized mannitol ester of bortezomib did not meet a long-felt need was both perfunctory and clearly erroneous." The Federal Circuit explained that "[e]vidence of long-felt need is particularly probative of obviousness when it demonstrates both that a demand existed for the patented invention, and that others tried but failed to satisfy that demand."12 Here, the Federal Circuit found that there was "no dispute that there was a long-felt need for a product to treat multiple myeloma," and that while "it is agreed that bortezomib is the effective product in the body, bortezomib alone is not an available product."

Furthermore, the Federal Circuit stated that the district court "clearly erred in attributing Velcade®'s commercial success to bortezomib alone, as bortezomib is not a viable commercial product and had been denied FDA approval because of its instability." Instead, the Federal Circuit explained that "[t]he D-mannitol ester was responsible for Velcade®'s successful results, for the D-mannitol ester is necessary to provide the required solubility and stability."

Thus, "[o]n the entirety of the record," the Federal Circuit concluded "that the district court clearly erred in finding that a person of ordinary skill would obviously make the D-mannitol ester in order to solve the problem of providing an effective form of bortezomib. The unexpected properties of an unexpectedly produced new compound, and the ensuing pharmaceutical efficacy and benefit, negate the district court's ruling of obviousness."13 Accordingly, the Federal Circuit reversed the district court's invalidity determination.

Footnotes



1Millennium Pharm., Inc. v. Sandoz Inc., No. 15-2066, slip op. at 4 (Fed. Cir. July 17, 2017).
2Id. at 8 (citation omitted).
3Id. at 11.
4Id.
5Id. at 14
6Id. at 13.
7Id. at 14-15 (citations omitted).
8Id. at 16.
9Id. at 17.
10Id. at 18 (quotation omitted).
11Id. at 19.
12Id. at 19 (quotation omitted).
13Id. at 21.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.